Darobactine: eine neue Antibiotikaklasse in Entwicklung

The discovery pipeline for novel antibiotics runs dry, while antimicrobial resistances increase, causing 1.3 million deaths per year globally. Even in the European Economic Area with generally intact health care, more than 35,000 people die per year with numbers expected to rise. Especially certain...

Full description

Saved in:
Bibliographic Details
Published in:Biospektrum 2023-09, Vol.29 (5), p.539-541
Main Authors: Seyfert, Carsten E., Porten, Christoph, Müller, Rolf
Format: Article
Language:ger
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The discovery pipeline for novel antibiotics runs dry, while antimicrobial resistances increase, causing 1.3 million deaths per year globally. Even in the European Economic Area with generally intact health care, more than 35,000 people die per year with numbers expected to rise. Especially certain pathogenic Gram-negative bacteria are to blame. Optimized versions of the innovative natural product class of darobactins acting selectively at a novel target on the bacterial outer membrane may provide novel treatment options.
ISSN:0947-0867
1868-6249
DOI:10.1007/s12268-023-1988-6